drugset / Trial / NCT00146068

EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis

NCT00146068

Phase 4 Completed 30 enrolled University of North Carolina
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the safety, tolerability and efficacy of a combination therapy interferon beta-1a(Avonex) plus simvastatin (Zocor) vs. interferon beta-1a plus placebo in patients with clinically isolated syndrome suggestive of Multiple Sclerosis.

Timeline

Start
2004-09
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Simvastatin Small molecule Oral
Background Interferon beta-1a Protein / enzyme biologic 30 mg Intramuscular

Indications